Tolerability and acceptance of prolonged low/delayed mitoxantrone regimens in patients with worsening multiple sclerosis

European Neurology

Volumn 65, Issue 1, 2011, Pages 40-45

  Zecca, Chiara ^a   Petrini, Liliane ^a   Limoni, Costanzo ^a   Staedler, Claudio ^a   Gobbi, Claudio ^a  

^a Ospedale Civico Lugano   (Switzerland)

Author keywords

Mitoxantrone; Multiple sclerosis

Indexed keywords

GADOLINIUM; MITOXANTRONE;

ALOPECIA; AMENORRHEA; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DEPRESSION; DISEASE COURSE; DISEASE EXACERBATION; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; FOLLOW UP; HUMAN; LEUKEMIA; LEUKOCYTE COUNT; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; RELAPSE; REMISSION; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ADULT; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MITOXANTRONE; MULTIPLE SCLEROSIS; PATIENT ACCEPTANCE OF HEALTH CARE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 78650631147     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000323013     Document Type: Article

References (20)

1. Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW: The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003; 61: 1332-1338.
2. Ghalie RG, Edan G, Laurent M, Mauch E, Eisenman S, Hartung HP, Gonsette RE, Butine MD, Goodkin DE: Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002; 59: 909-913.
3. Pascual AM, Tellez N, Bosca I, Mallada J, Belenguer A, Abellan I, Sempere AP, Fernandez P, Magraner MJ, Coret F, Sanz MA, Montalban X, Casanova B: Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. Mult Scler 2009; 15: 1303-1310.
4. Cocco E, Sardu C, Gallo P, Capra R, Amato MP, Trojano M, Uccelli A, Marrosu MG: Frequency and risk factors of mitoxantrone-in-duced amenorrhea in multiple sclerosis: the FEMIMS study. Mult Scler 2008; 14: 1225-1233.
5. Ellis R, Boggild M: Therapy-related acute leukaemia with mitoxantrone: what is the risk and can we minimise it? Mult Scler 2009; 15: 505-850.
6. Kingwell E, Koch M, Leung B, Isserow S, Geddes J, Rieckmann P, Tremlett H: Card iotoxicity and other adverse events associated with mitoxantrone treatment for MS. Neurology 2010; 74: 1822-1826.
7. Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW: Evidence Report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple scerosis. Neurology 2010; 74: 1463-1470.
8. Ghalie RG, Mauch E, Edan G, Hartung HP, Gonsette RE, Eisenmann S, Le Page, E, Butine MD, De Goodkin DE: A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 2002; 8: 441-445.
9. Zingler VC, Strupp M, Jahn K, Gross A, Hohlfeld R, Brandt T: The effect of combined mitoxantrone and methylprednisolone therapy in primary and secondary progressive multiple sclerosis: an applied study in 65 patients. Nervenarzt 2005; 76: 740-747.
10. Gonsette R, Demontly L: Immunosuppression with mitoxantrone in multiple sclerosis: a pilot study for 2 years in 22 patients. Neurology 1990; 40: 261.
11. Mauch E, Kornhuber HH, Krapf H, Fetzer U, Laufen H: Treatment of multiple sclerosis with mitoxantrone. Eur Arch Psychiatry Clin Neurosci 1992; 242: 96-102.
12. Noseworthy JH, Hopkins MB, Vandervoort MK, et al: An open-trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology 1993; 43: 1401-1406.
13. Bastianello S, Pozzilli C, D'Andrea F, et al: A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. Can J Neurol Sci 1994; 21: 266-270.
14. Millefiorini E, Gasperini C, Pozzilli C, D'Andrea F, Bastianello S, Trojano M, Morino S, Morra VB, Bozzao A, Calo A, Bernini ML, Gambi D, Prencipe M: Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997; 244: 153-159.
15. Edan G, Miller D, Clanet M, Confavreux C, Lyon-Caen O, Lubetzki C, Brochet B, Berry I, Rolland Y, Froment JC, Cabanis E, Iba-Zizen MT, Gandon JM, Lai HM, Moseley I, Sabouraud O: Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997; 62: 112-118.
16. Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, Krapf H, Zwingers T: Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360: 2018-2025.
17. Cohen A, Mikol D: Mitoxantrone treatment of multiple sclerosis: safety considerations. Neurology 2004; 63(suppl 6):S28-S32.
18. Le Page E, Leray E, Taurin G, Coustans M, Chaperon J, Morrissey SP, Edan G: Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry 2008; 79: 52-56.
19. Arnold DL, Campagnolo D, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, Vollmer T: Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS. J Neurol 2008; 255: 1473-1478.
20. Vollmer T, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, Campagnolo D, Deutsch F, Arnold DL: Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler 2008; 14: 663-670.